Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Isobe, Aki ^a   Sawada, Kenjiro ^a   Kinose, Yasuto ^a   Ohyagi Hara, Chifumi ^a,b   Nakatsuka, Erika ^a   Makino, Hiroshi ^c   Ogura, Tomonori ^c   Mizuno, Tomoko ^c   Suzuki, Noriko ^c   Morii, Eiichi ^a   Nakamura, Koji ^a   Sawada, Ikuko ^a   Toda, Aska ^a   Hashimoto, Kae ^a   Mabuchi, Seiji ^a   Ohta, Tsuyoshi ^d   Morishige, Ken Ichirou ^c   Kurachi, Hirohisa ^d   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JCHO Osaka Hospital   (Japan)

^c GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD11B ANTIGEN; CD14 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PLATINUM COMPLEX; TAXANE DERIVATIVE; TOCILIZUMAB; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; ASCITES; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURGERY; CELL INVASION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARIAN CANCER CELL LINE; OVARY CANCER; OVARY CARCINOMA; PARACRINE SIGNALING; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; YOUNG ADULT; BIOLOGICAL MODEL; BIOSYNTHESIS; CANCER GRADING; CANCER STAGING; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD11B; ANTIGENS, CD14; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-6; MACROPHAGES; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PARACRINE COMMUNICATION; PHENOTYPE; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84922614400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118080     Document Type: Article

References (33)

1. Maccio A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58: 133-147. doi: 10.1016/j. cyto.2012.01.015 PMID: 22349527
2. Dijkgraaf EM, Welters MJ, Nortier JW, van der Burg SH, Kroep JR (2012) Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Current pharmaceutical design 18: 3816-3827. PMID: 22591418
3. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, et al. (1994) Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73: 1882-1888. PMID: 8137215
4. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, et al. (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. British journal of cancer 71: 354-356. PMID: 7841052
5. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, et al. (2006) Signal transducers and activators of transcription pathway activation in drug-resistant ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 5055-5063. PMID: 16951221
6. Rath KS, Funk HM, Bowling MC, Richards WE, Drew AF (2010) Expression of soluble interleukin-6 receptor in malignant ovarian tissue. American journal of obstetrics and gynecology 203: 230 e231-238. doi: 10.1016/j.ajog.2010.03.034 PMID: 20471626
7. Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer treatment reviews 38: 904-910. doi: 10.1016/j.ctrv.2012.04.007 PMID: 22651903
8. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, et al. (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. International immunopharmacology 5: 1731-1740. PMID: 16102523
9. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, et al. (2009) Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 5426-5434. doi: 10.1158/1078-0432.CCR-09-0287 PMID: 19706815
10. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, et al. (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106: 2627-2632. PMID: 15998837
11. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Annals of the rheumatic diseases 66: 1162-1167. PMID: 17485422
12. Erroi A, Sironi M, Chiaffarino F, Chen ZG, Mengozzi M, et al. (1989) IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma. International journal of cancer Journal international du cancer 44: 795-801. PMID: 2583859
13. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O (1990) Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer research 50: 6959-6965. PMID: 2208162
14. Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, et al. (2012) Elevated and secreted phospholipase A(2) activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 26: 3306-3320. doi: 10.1096/fj.12-207597 PMID: 22767227
15. Ataie-Kachoie P, Morris DL, Pourgholami MH (2013) Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies. PloS one 8: e60817. doi: 10.1371/journal.pone.0060817 PMID: 23593315
16. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, et al. (2007) Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer research 67: 5708-5716. PMID: 17575137
17. Bak SP, Walters JJ, Takeya M, Conejo-Garcia JR, Berwin BL (2007) Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer research 67: 4783-4789. PMID: 17510407
18. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nature reviews Cancer 4: 71-78. PMID: 14708027
19. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, TakeyaM (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathology international 59: 300-305. doi: 10.1111/j.1440-1827.2009.02369.x PMID: 19432671
20. Shepherd TG, Theriault BL, Campbell EJ, NachtigalMW(2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nature protocols 1: 2643-2649. PMID: 17406520
21. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. PMID: 11846609
22. Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, et al. (1993) Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 72: 2433-2440. PMID: 8402460
23. Wang Y, Li L, Guo X, Jin X, Sun W, et al. (2012) Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59: 228-236. doi: 10.1016/j.cyto.2012.04.020 PMID: 22595649
24. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nature reviews Cancer 9: 239-252. doi: 10.1038/nrc2618 PMID: 19279573
25. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, et al. (2012) Paraneoplastic thrombocytosis in ovarian cancer. The New England journal of medicine 366: 610-618. doi: 10.1056/NEJMoa1110352 PMID: 22335738
26. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 6083-6096. doi: 10.1158/1078-0432.CCR-11-0945 PMID: 21795409
27. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, et al. (2014) Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. International journal of cancer Journal international du cancer 134: 32-42. doi: 10.1002/ijc.28335 PMID: 23784932
28. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. British journal of cancer 100: 134-144. doi: 10.1038/sj.bjc.6604794 PMID: 19088723
29. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, et al. (2009) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 7144-7152. doi: 10.1158/1078-0432. CCR-09-1483 PMID: 19934301
30. Oguro T, Ishibashi K, Sugino T, Hashimoto K, Tomita S, et al. (2013) Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression. European journal of cancer 49: 1715-1724. doi: 10.1016/j.ejca.2012.11.038 PMID: 23274199
31. Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, et al. (2013) Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31: e69-72.
32. Hall M, Gourley C, McNeish I, Ledermann J, Gore M, et al. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. British journal of cancer 108: 250-258. doi: 10.1038/bjc.2012.541 PMID: 23385789
33. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans R, et al. (2013) Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer research 73: 2480-2492. doi: 10.1158/0008-5472.CAN-12-3542 PMID: 23436796